Management & Board


Our pipeline includes a CTLA-4 antibody at the advanced pre-clinical stage and we promote additional immune-therapy antibodies which are at an earlier pre-clinical stage:

Immune Oncology

Clinical Indications:
Metastatic melanoma

Immune Oncology

Aviv Boim | CEO

Aviv Boim has served as our Chief Executive Officer since October 2010. He joined Tikcro in January 2008. From 2008 to 2012, he served as a member of the board of directors and the executive committee of BioCancell, a clinical stage biotechnology company that focuses on the oncology field. Mr. Boim led the selection, term negotiation and pre-clinical development plans of a number of oncology projects performed with leading Israeli universities, including for cancer vaccines, molecular biomarkers and the development of therapeutic candidates. From 1998 to 2007, he served as the Chief Financial Officer of Orckit. Mr. Boim holds a B.A. and an M.A. in economics and management from Tel Aviv University and an L.L.B. from Tel Aviv University Law School.

Izhak Tamir | Chairman of the Board

Izhak Tamir has served as Chairman of our Board of Directors since January 2000 and served as our Chief Executive Officer from August 2003 to December 2007. He co-founded Orckit Communications Ltd. (“Orckit”) in 1990 and served as President and a Director until 2014. Mr. Tamir served as Chairman of the Board of Orckit-Corrigent Ltd., a subsidiary of Orckit, from 2001 to 2014, and as Chief Executive Officer of Orckit-Corrigent Ltd. from 2007 to 2014 and as a Director of Gilat Satellite Networks Ltd. from 2005 to 2012. From 1987 until 1989, Mr. Tamir was employed by Comstream Inc., in San Diego, California.  From 1985 until 1987, he was vice president of A.T. Communication Channels Ltd., a subsidiary of Bezeq.  From 1978 to 1985, he was a senior engineer in the Israeli Government. Mr. Tamir holds an engineering degree from the Technion, and an M.B.A. from Tel Aviv University.

Eric Paneth | Director

Eric Paneth has served as one of our Directors since January 2000 and served as our Chief Executive Officer from November 2008 to October 2010.  He co-founded Orckit in 1990 and served as Chief Executive Officer and a Director until 2014.  From 1975 until 1983, Mr. Paneth was a senior engineer in the Israeli Government, and from 1985 to 1990, he was a technical department head in the Israeli Government.  From 1983 until 1985, he was employed by Linkabit Inc. in San Diego, California.  Mr. Paneth holds an advanced engineering degree from the Technion.

Liat Hadad | Director

Liat Hadad has served as one of our external directors since September 2009. Since April 2017, Ms. Hadad has served as Director of Business Development at Ramot, the technology transfer arm of Tel Aviv University.  From 2016 to 2017, she served as Director of Business Development at Agan Aroma & Fine Chemicals.  From 2010 to 2014, Ms. Hadad served as VP of Marketing and Business Development at Allium Medical. From May 2009 to March 2010, she served as Director of Business Development at McCann Erickson Digital Israel. From 2001 to 2008, Ms. Hadad served as an associate in the Life Sciences Division of Giza Venture Capital. From 1999 to 2001, she was a Business Development and Marketing Manager at Ltd. From 1996 to 1998, she was a System Integrations Project Manager at IBM Israel. Ms. Hadad holds a B.A. in sociology, anthropology and political science and an Executive M.B.A. in entrepreneurial studies, marketing and finance, both from Tel Aviv University.

Dr. Rami Skaliter | Director

Dr. Rami Skaliter has served as one of our external directors since January 2016. Since June 2017 he has served as the CEO of Cell Cure Neurosciences Ltd. Before, since 1995 he has served in various executive roles at Quark Pharmaceuticals, including Vice President and Executive Vice President of Research & Development, and currently serves as the Chief Operating Officer. Under his leadership, Quark’s research and development unit generated most of its current product pipeline. Dr. Skaliter holds a B.Sc. in biology from the Ben-Gurion University and an M.Sc. and Ph.D. in biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. From 1993 to 1995, Dr. Skaliter completed a post-doctoral fellowship at Stanford University.

© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet